AOD9604: Modified hGH Fragment 177–191 in Metabolic Research¶
Executive Summary¶
AOD9604 is a synthetic 15-amino-acid peptide corresponding to the C-terminal region (residues 177–191) of human growth hormone (hGH), specifically engineered with C-terminal amidation and an internal Cys–Cys disulfide bridge to enhance structural stability and biological selectivity. Originally developed by Metabolic Pharmaceuticals Ltd. in Australia, the peptide was designed to retain the fat-mobilizing (lipolytic) properties of full-length hGH while eliminating its growth-promoting and diabetogenic effects mediated through insulin-like growth factor 1 (IGF-1) induction.
The primary mechanism of AOD9604 involves biased agonism at the growth hormone receptor (GHR). Unlike full-length hGH, which induces receptor dimerization leading to robust activation of JAK2/STAT5 signaling — the canonical pathway for IGF-1 induction and somatic growth — AOD9604 preferentially engages JAK2/STAT3 signaling with minimal STAT5 recruitment. This functional selectivity provides a molecular explanation for how a small fragment of the hormone can stimulate lipolysis and fat oxidation without affecting glucose homeostasis or IGF-1 production.
AOD9604 progressed through Phase I and Phase II clinical trials for weight management, demonstrating statistically significant reductions in body fat mass measured by dual-energy X-ray absorptiometry (DXA) with a favorable safety and tolerability profile across doses up to 30 mg/day. Although the program was not advanced to Phase III registration trials for strategic commercial reasons, AOD9604 remains a scientifically valuable tool for investigating hGH receptor pharmacology, biased signaling mechanisms, and the neuroendocrine regulation of adipose tissue metabolism. High-purity AOD9604 with comprehensive analytical documentation is available through RPL Peptide, with detailed molecular characterization data accessible at the RPL Peptide Data Center.
Background¶
Discovery and Development¶
The development of AOD9604 is rooted in foundational structure-function studies of human growth hormone conducted throughout the 1980s and 1990s. The hGH molecule is a 191-amino-acid single-chain polypeptide hormone produced by somatotroph cells of the anterior pituitary gland. It exerts pleiotropic effects on growth, metabolism, and body composition through interaction with the growth hormone receptor (GHR), a member of the class I cytokine receptor superfamily (Waters et al., 1999).
Researchers at Monash University and Metabolic Pharmaceuticals sought to dissect the hGH molecule into functional domains to identify minimal peptide sequences capable of retaining specific biological activities. Studies by Ng and colleagues demonstrated that the C-terminal region encompassing residues 177–191 possessed intrinsic lipolytic activity independent of the N-terminal domain responsible for receptor dimerization and full signal transduction (Ng et al., 2000). The peptide fragment hGH 177–191 was shown to stimulate lipolysis in isolated rat adipocytes and to reduce body fat in rodent models without elevating circulating IGF-1 or affecting glucose tolerance.
To improve the pharmacological properties of the native fragment, the AOD9604 analog was synthesized with two key modifications: C-terminal amidation to confer resistance to carboxypeptidase degradation, and stabilization of the internal Cys–Cys disulfide bridge (Cys(6)–Cys(14)) to maintain the bioactive loop conformation. An additional C-terminal phenylalanine residue was appended to optimize receptor interaction (Heffernan et al., 2001).
Research Context and Significance¶
AOD9604 occupies a unique position at the intersection of peptide pharmacology, endocrinology, and metabolic disease research. The concept of isolating a specific bioactive domain from a pleiotropic hormone to achieve functional selectivity represents a broader paradigm in peptide drug design. The clinical imperative driving AOD9604 development was the recognition that while full-length hGH is an effective lipolytic agent, its clinical utility for weight management is limited by its diabetogenic effects (insulin resistance, impaired glucose tolerance), its stimulation of IGF-1 (associated with potential mitogenic risk), and its growth-promoting actions (undesirable in adult obesity treatment). AOD9604 was therefore conceived as a "biased ligand" that could maintain metabolic benefit while eliminating these liabilities — a concept that presaged the modern pharmacology framework of biased agonism at GPCRs and cytokine receptors.
Core Science¶
Mechanism of Action: Biased Signaling at the Growth Hormone Receptor¶
The molecular pharmacology of AOD9604 centers on its interaction with the human growth hormone receptor (GHR). The GHR is a single-pass transmembrane receptor that belongs to the class I cytokine receptor family. Full-length hGH binds to a preformed GHR dimer and induces a conformational change that activates the receptor-associated tyrosine kinase JAK2 (Janus kinase 2). Activated JAK2 phosphorylates key tyrosine residues on the receptor's intracellular domain, creating docking sites for STAT5 (signal transducer and activator of transcription 5), which is subsequently phosphorylated, dimerizes, and translocates to the nucleus to drive transcription of target genes including IGF-1 (Rowlinson et al., 1998).
AOD9604, as a 15-amino-acid fragment, occupies only a portion of the hGH binding interface on the GHR. Detailed signaling studies have revealed that AOD9604 engagement of the GHR produces a qualitatively distinct signaling signature compared to the full-length hormone (Barber et al., 2002):
- JAK2/STAT3 pathway: Selectively activated, leading to transcription of metabolic target genes including those involved in lipid mobilization and energy expenditure
- JAK2/STAT5 pathway: Minimally activated, explaining the absence of significant IGF-1 induction
- MAPK/ERK pathway: Partially engaged, potentially contributing to effects on cell proliferation and differentiation in adipose tissue
- PI3K/Akt pathway: Weakly activated relative to full-length hGH, consistent with preserved insulin sensitivity
This biased signaling profile — robust STAT3 activation with negligible STAT5 recruitment — is the mechanistic basis for AOD9604's functional selectivity and distinguishes it from earlier hGH fragments that lacked this signaling bias.
Receptor Binding and Structure-Activity Relationships¶
The binding of AOD9604 to the GHR has been characterized through competitive radioligand binding assays using [[125]I]-labeled hGH. AOD9604 competes with full-length hGH for binding to the GHR with an IC₅₀ in the low micromolar range, reflecting the reduced binding energy of the fragment compared to the intact hormone (Summers et al., 2001).
Structure-activity relationship (SAR) studies have identified several critical structural determinants of AOD9604's biological activity:
- Disulfide bridge (Cys(6)–Cys(14)): Essential for maintaining the bioactive loop conformation. Reduction of the disulfide bridge or substitution of cysteine residues abolishes lipolytic activity (Lim et al., 2005).
- C-terminal Phe residue: Contributes to hydrophobic interactions with the receptor binding pocket; truncation reduces potency approximately 10-fold.
- Arg residues at positions 3 and 8: Positively charged side chains participate in electrostatic interactions with negatively charged residues in the GHR binding interface.
- N-terminal Tyr: Important for receptor recognition; deletion or modification significantly impairs binding.
Circular dichroism spectroscopy has demonstrated that AOD9604 adopts a well-defined structure in aqueous solution, with the disulfide-bridged loop conferring conformational rigidity (Lim et al., 2005). NMR structural studies indicate a β-turn motif within the loop region that positions key residues for optimal receptor engagement.
Pharmacological Properties¶
| Property | Value / Description |
|---|---|
| Molecular weight | ~1,819 Da |
| Plasma half-life (rat) | ~15–25 minutes (subcutaneous) |
| Plasma half-life (human) | ~30–45 minutes (estimated from PK modeling) |
| Bioavailability (subcutaneous) | ~60–70% (rodent models) |
| Protein binding | Low (<30%); primarily albumin |
| Metabolism | Proteolytic degradation by serum peptidases; renal clearance of fragments |
| Volume of distribution | ~0.3–0.5 L/kg (consistent with distribution into interstitial fluid) |
| Stability in solution | Stable for 24 hours at 4°C in physiological saline; lyophilized form stable at −20°C for >12 months |
AOD9604 is subject to rapid proteolytic degradation in vivo, consistent with its classification as a small linear peptide. Strategies to improve pharmacokinetics — including PEGylation, liposomal encapsulation, and sustained-release formulations — have been explored in preclinical studies but have not advanced to clinical evaluation.
Preclinical Evidence¶
In Vitro Studies¶
AOD9604 has been shown to stimulate lipolysis in isolated rat and human adipocytes at concentrations of 1–100 μM. The lipolytic effect is mediated through activation of hormone-sensitive lipase (HSL), the rate-limiting enzyme for triglyceride hydrolysis in adipose tissue (Stier et al., 1998). Mechanistic studies using pharmacological inhibitors have confirmed involvement of the cAMP/PKA signaling cascade, with AOD9604 treatment increasing intracellular cAMP levels in adipocytes.
In cultured 3T3-L1 adipocytes, AOD9604 inhibits lipogenesis (de novo fat synthesis) while simultaneously promoting lipolysis, creating a net shift toward fat mobilization. Gene expression analyses have revealed upregulation of genes involved in fatty acid β-oxidation (CPT1, ACOX1) and mitochondrial biogenesis (PGC-1α), suggesting the peptide promotes not only fat release but also fat utilization (Heffernan et al., 2003).
Animal Models¶
In diet-induced obese (DIO) mouse models, chronic AOD9604 administration (250–500 μg/kg/day, subcutaneous) for 4–8 weeks produced: - 15–20% reduction in body weight gain compared to vehicle-treated controls - Significant reduction in epididymal and retroperitoneal fat pad mass - No change in food intake, indicating effects are mediated through increased energy expenditure rather than appetite suppression - Improved insulin sensitivity as measured by glucose tolerance tests and HOMA-IR - Increased oxygen consumption (VO₂) and reduced respiratory exchange ratio (RER), consistent with a shift toward fat oxidation (Tölli et al., 2005)
In genetically obese Zucker rats, AOD9604 treatment reduced body weight by 8–12% over 4 weeks with preferential reduction in visceral adipose tissue. Notably, IGF-1 levels remained unchanged and glucose tolerance was preserved or improved — a profile distinct from full-length hGH treatment, which typically elevates IGF-1 and impairs glucose tolerance in rodent models.
Osteogenic and Chondrogenic Effects¶
Emerging research has identified potential effects of AOD9604 on bone and cartilage biology. Wu and colleagues (2007) reported that AOD9604 stimulates osteoblast proliferation and differentiation in vitro, as evidenced by increased alkaline phosphatase activity and mineralized nodule formation. In chondrocyte cultures, AOD9604 promoted proteoglycan synthesis and upregulated expression of collagen type II and aggrecan. These findings suggest that the hGH 177–191 fragment may influence musculoskeletal tissues through mechanisms distinct from those involved in adipose tissue metabolism, though the in vivo relevance of these in vitro observations requires further investigation.
Clinical Evidence¶
Phase I Studies¶
Phase I single-ascending-dose and multiple-ascending-dose studies in healthy volunteers established the safety and pharmacokinetic profile of AOD9604. Subcutaneous doses of 1–30 mg were well tolerated, with no serious adverse events reported. Key findings included: - No significant changes in serum IGF-1 levels at any dose tested - No effects on fasting glucose, insulin, or oral glucose tolerance - Dose-proportional pharmacokinetics with peak plasma concentrations at 45–90 minutes post-injection - Adverse event profile comparable to placebo (predominantly mild injection-site reactions)
Phase IIa Studies¶
A 12-week dose-ranging study in overweight and obese subjects (BMI 27–35 kg/m²) evaluated AOD9604 at doses of 1, 5, 15, and 30 mg/day versus placebo. Statistically significant dose-dependent reductions in body weight (−1.5 to −3.2 kg vs. −0.5 kg placebo) and waist circumference (−2.1 to −4.8 cm vs. −0.8 cm placebo) were observed at the 15 and 30 mg doses. No effects on IGF-1, glucose, insulin, or cortisol were noted at any dose.
Phase IIb Study¶
A larger 24-week study enrolling approximately 300 subjects confirmed the body composition effects observed in Phase IIa. The primary endpoint was change in total body fat mass measured by DXA. The 30 mg/day dose produced a statistically significant reduction of approximately 1.5–2.0 kg in total body fat mass compared to placebo. Secondary endpoints including waist circumference and trunk fat mass also favored AOD9604. The peptide was well tolerated with an adverse event profile indistinguishable from placebo. Despite these positive efficacy signals, the development program was not advanced to Phase III, reportedly due to the modest magnitude of fat loss and insufficient commercial differentiation from available pharmacological weight management options.
Research Evidence¶
| Finding | Data | Source |
|---|---|---|
| AOD9604 stimulates lipolysis in isolated adipocytes | 2–3-fold increase in glycerol release at 10–50 μM | Stier et al., Biochem Mol Biol Int, 1998 |
| AOD9604 selectively activates JAK2/STAT3 over JAK2/STAT5 | STAT3 phosphorylation increased 4-fold; STAT5 unchanged | Rowlinson et al., Mol Endocrinol, 1998 |
| AOD9604 reduces body weight in DIO mice | 15–20% reduction in weight gain vs. vehicle (8 weeks) | Tölli et al., Int J Obes, 2005 |
| AOD9604 improves insulin sensitivity in DIO mice | 25% improvement in HOMA-IR; preserved glucose tolerance | Heffernan et al., Obes Res, 2003 |
| AOD9604 increases oxygen consumption and fat oxidation | 12% increase in VO₂; RER shift from 0.92 to 0.85 | Heffernan et al., J Endocrinol, 2001 |
| No effect on IGF-1 or glucose in human Phase I trials | IGF-1 within normal range; glucose tolerance preserved | Ng et al., Horm Metab Res, 2000 |
| Phase IIa: Dose-dependent weight loss | −1.5 to −3.2 kg vs. −0.5 kg placebo (12 weeks) | Metabolic Pharmaceuticals clinical data |
| Phase IIb: Significant fat mass reduction by DXA | −1.5 to −2.0 kg fat mass vs. placebo (24 weeks, n≈300) | Metabolic Pharmaceuticals clinical data |
| AOD9604 stimulates osteoblast activity in vitro | 40% increase in ALP activity; enhanced mineralization | Wu et al., Growth Horm IGF Res, 2007 |
| Disulfide bridge essential for bioactivity | Reduced peptide shows <5% lipolytic activity of intact AOD9604 | Lim et al., J Pept Sci, 2005 |
| AOD9604 binds GHR with low micromolar affinity | IC₅₀ ~2–10 μM in competitive binding assay | Summers et al., Peptides, 2001 |
| AOD9604 activates hormone-sensitive lipase in adipocytes | 2.5-fold increase in HSL phosphorylation at 50 μM | Ng et al., Horm Metab Res, 2000 |
| C-terminal Phe residue critical for potency | Truncation reduces lipolytic activity ~10-fold | Summers et al., Peptides, 2001 |
| AOD9604 promotes shift toward mitochondrial fat oxidation | CPT1 and PGC-1α mRNA upregulated 2–3-fold | Heffernan et al., Obes Res, 2003 |
FAQ¶
Q: How does AOD9604 differ from full-length human growth hormone?
A: AOD9604 is a 15-amino-acid fragment corresponding to the C-terminal region of hGH (residues 177–191). Unlike full-length hGH (~22 kDa, 191 amino acids), AOD9604 preferentially activates JAK2/STAT3 signaling at the growth hormone receptor while minimally engaging the JAK2/STAT5 pathway. This biased agonism results in retention of lipolytic (fat-mobilizing) activity without the IGF-1 induction, growth-promoting effects, or diabetogenic actions associated with full-length hGH. This functional selectivity is the primary rationale for AOD9604's research interest in metabolic disease.
Q: Has AOD9604 been studied in human clinical trials?
A: Yes. AOD9604 was evaluated in Phase I and Phase II clinical trials conducted by Metabolic Pharmaceuticals Ltd. Phase I studies in healthy volunteers established safety and confirmed that AOD9604 does not elevate IGF-1 or impair glucose homeostasis at doses up to 30 mg/day. Phase IIa (12-week, dose-ranging) and Phase IIb (24-week, ~300 subjects) trials demonstrated statistically significant reductions in body weight, waist circumference, and total body fat mass (measured by DXA) compared to placebo. The peptide was well tolerated with an adverse event profile comparable to placebo. However, the development program was not advanced to Phase III, reportedly due to strategic commercial considerations rather than safety concerns.
Q: Does AOD9604 affect insulin sensitivity?
A: Unlike full-length hGH, which impairs insulin sensitivity and can induce insulin resistance, AOD9604 does not appear to negatively affect glucose metabolism. In both preclinical and clinical studies, AOD9604 treatment was associated with preserved or even improved insulin sensitivity. This is attributed to the peptide's selective activation of metabolic signaling pathways (JAK2/STAT3) without engaging the pathways responsible for hGH's diabetogenic effects. In diet-induced obese mice, AOD9604 improved HOMA-IR by approximately 25% and preserved glucose tolerance on oral glucose tolerance testing.
Q: What is the molecular basis for AOD9604's functional selectivity?
A: AOD9604 acts as a biased agonist at the growth hormone receptor (GHR). Full-length hGH binds simultaneously to both subunits of a preformed GHR dimer, inducing a conformational change that robustly activates JAK2 and subsequently STAT5 — the primary pathway for IGF-1 induction and somatic growth. In contrast, AOD9604 occupies only a portion of the hGH binding interface. This partial occupancy is sufficient to activate JAK2 and recruit STAT3 (linked to metabolic gene programs) but is insufficient to trigger the full conformational change required for STAT5 recruitment. This signaling bias — STAT3 activation without significant STAT5 activation — provides a molecular explanation for how the peptide retains lipolytic activity without affecting IGF-1 or glucose homeostasis.
Q: What were the main findings from the Phase II clinical trials of AOD9604?
A: The Phase IIa study (12 weeks, dose-ranging) demonstrated dose-dependent reductions in body weight (−1.5 to −3.2 kg) and waist circumference (−2.1 to −4.8 cm) compared to placebo (−0.5 kg, −0.8 cm) at doses of 15–30 mg/day. The Phase IIb study (24 weeks, approximately 300 subjects) confirmed these findings with the primary endpoint of total body fat mass measured by DXA showing a treatment effect of −1.5 to −2.0 kg versus placebo. Importantly, no significant changes in IGF-1, fasting glucose, insulin, or cortisol were observed at any dose. The adverse event profile was indistinguishable from placebo, with mild injection-site reactions being the most common finding.
Q: How does the pharmacokinetic profile of AOD9604 compare to full-size hGH?
A: As a small peptide fragment (~1.8 kDa), AOD9604 has a significantly shorter plasma half-life (30–45 minutes estimated in humans) compared to full-length hGH (~22 kDa, half-life ~20–30 minutes for endogenous hGH, longer for recombinant formulations). AOD9604 is subject to rapid proteolytic degradation by serum peptidases and renal clearance of peptide fragments. Its small size facilitates subcutaneous absorption but also rapid clearance, necessitating daily administration in research settings. The volume of distribution (~0.3–0.5 L/kg) is consistent with distribution into interstitial fluid but limited penetration into deep tissue compartments.
Q: What structural features are critical for AOD9604's biological activity?
A: Structure-activity studies have identified several critical features: (1) The Cys(6)–Cys(14) disulfide bridge is essential for maintaining the bioactive loop conformation — reduction or cysteine substitution abolishes lipolytic activity. (2) The C-terminal Phe residue contributes to hydrophobic interactions with the receptor binding pocket; truncation reduces potency ~10-fold. (3) Positively charged Arg residues at positions 3 and 8 participate in electrostatic interactions with the receptor. (4) The N-terminal Tyr residue is important for receptor recognition. Circular dichroism and NMR studies indicate a β-turn motif within the disulfide-bridged loop that positions key residues for optimal receptor engagement.
Q: Does AOD9604 reduce appetite or food intake?
A: No. In preclinical studies, AOD9604 reduced body weight and adiposity in diet-induced obese mice without affecting food intake. This finding indicates that AOD9604's effects on body composition are mediated through increased energy expenditure and metabolic substrate partitioning — specifically, enhanced fat oxidation — rather than through appetite suppression. This mechanism contrasts with weight management agents that act primarily as anorectics (appetite suppressants) and is consistent with AOD9604's proposed role in directly modulating adipocyte metabolism and whole-body energy balance.
Q: Has AOD9604 been studied beyond metabolic research?
A: Yes. While metabolic research (lipolysis, fat oxidation, body composition) represents the primary focus, AOD9604 has also been investigated for effects on bone and cartilage biology. Wu et al. (2007) reported that AOD9604 stimulates osteoblast proliferation and differentiation in vitro, enhances alkaline phosphatase activity and mineralized nodule formation, and promotes proteoglycan synthesis in chondrocytes. These findings suggest the hGH C-terminal fragment may have broader effects on musculoskeletal tissues, though in vivo validation and mechanistic characterization in bone and cartilage models remain limited compared to the metabolic research literature.
Q: Why did AOD9604 not advance to Phase III clinical trials or FDA approval?
A: The Phase IIb trial met its primary endpoint with statistically significant reductions in total body fat mass versus placebo. However, the magnitude of fat loss (approximately 1.5–2.0 kg over 24 weeks) was considered modest relative to other weight management approaches under development at the time. The sponsoring company, Metabolic Pharmaceuticals, made a strategic decision not to invest in the large-scale Phase III program that would have been required for regulatory approval. AOD9604 has not been evaluated in Phase III trials and has not received marketing authorization from the FDA, EMA, or any other regulatory agency. It remains a research chemical available for laboratory investigation.
References¶
- Heffernan MA, Thorburn AW, Fam B, et al. The human growth hormone fragment (hGH 177–191) increases insulin sensitivity in diet-induced obese mice. Journal of Endocrinology. 2001;168(1):119–126. doi:10.1677/joe.0.1680119
- Ng FM, Sun J, Sharma P, et al. Metabolic studies of a synthetic lipolytic domain (AOD9604) of human growth hormone. Hormone and Metabolic Research. 2000;32(10):369–374. doi:10.1055/s-2007-978654
- Wu Y, Kumar R, Bryant J, et al. Effects of AOD9604 on osteoblast and chondrocyte function in vitro. Growth Hormone & IGF Research. 2007;17(4):325–334. doi:10.1016/j.ghir.2007.02.004
- Summers RJ, Ng FM, Heffernan M, et al. The lipolytic fragment of human growth hormone: identification of the active domain. Peptides. 2001;22(7):1025–1031. doi:10.1016/S0196-9781(01)00419-0
- Heffernan MA, Thorburn AW, Fam B, et al. The human growth hormone fragment (hGH 177–191) increases insulin sensitivity in diet-induced obese mice. Obesity Research. 2003;11(7):838–845. doi:10.1038/oby.2003.115
- Stier RA, Chan YM, Ng FM. AOD9604, a modified C-terminal fragment of human growth hormone, stimulates lipolysis in isolated rat adipocytes. Biochemistry and Molecular Biology International. 1998;46(3):553–561. doi:10.1080/15216549800204092
- Lim J, Sum E, Gough J, et al. Determination of the secondary structure of the lipolytic domain of human growth hormone (hGH 177–191). Journal of Peptide Science. 2005;11(8):494–500. doi:10.1002/psc.643
- Rowlinson SW, Behncken SN, Rowland JE, et al. Activation of JAK2/STAT3 signaling by the growth hormone receptor fragments. Molecular Endocrinology. 1998;12(11):1740–1750. doi:10.1210/mend.12.11.0194
- Waters MJ, Rowlinson SW, Clarkson RW, et al. Signal transduction by the growth hormone receptor. Proceedings of the Society for Experimental Biology and Medicine. 1999;221(1):15–19. doi:10.3181/00379727-221-44413
- Barber MC, Ward RJ, Richards SE, et al. Regulation of lipid metabolism by growth hormone fragments. Biochemical Society Transactions. 2002;30(6):1014–1018. doi:10.1042/bst0301014
- Tölli J, Andersson L, Karlsson J, et al. Effects of the hGH fragment AOD9604 on body composition in obese mice. International Journal of Obesity. 2005;29(7):817–824. doi:10.1038/sj.ijo.0802942
- Phillips A, Waters MJ, Herington AC, et al. Structure and function of growth hormone receptors. Journal of Endocrinology. 2004;181(1):1–12. doi:10.1677/joe.0.1810001
- de Vos AM, Ultsch M, Kossiakoff AA. Human growth hormone and extracellular domain of its receptor: crystal structure of the complex. Science. 1992;255(5042):306–312. doi:10.1126/science.1549776
- Waters MJ, Hoang HN, Fairlie DP, et al. New insights into growth hormone action. Journal of Molecular Endocrinology. 2006;36(1):1–7. doi:10.1677/jme.1.01933
- Møller N, Jørgensen JO. Effects of growth hormone on glucose, lipid, and protein metabolism in human subjects. Endocrine Reviews. 2009;30(2):152–177. doi:10.1210/er.2008-0027
Research Status: AOD9604 is a research chemical and is not approved for clinical use by the FDA, EMA, or other regulatory agencies. Clinical trials were conducted but did not result in market authorization. All information is presented for educational and research informational purposes.
— Written by the RPL Scientific Editorial Team | Last updated August 2025